Harpoon Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Corporate Update
HPN217 (BCMA) and HPN328 (DLL3) enrollment on track, with data updates and selection of recommended Phase 2 doses for both active clinical programs planned in 2023
Related news for (HARP)
- SHAREHOLDER NOTICE: Halper Sadeh LLC Investigates HARP, JNPR, TGAN
- SHAREHOLDER RIGHTS INVESTIGATION: Halper Sadeh LLC Investigates AMAM, AXNX, HARP, GRCL
- HARPOON THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Harpoon Therapeutics, Inc. – HARP
- SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates HARP, AMAM, AXNX
- Harpoon Therapeutics Strengthens Leadership Team